Special Issue "Recent Advances in Nuclear Factor Kappa-B (NF-kB) Inhibitors for Cancer Therapy"
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 3457
Nuclear Factor kappa-B is a critical transcription factor regulating numerous target genes, such as COX-2, VEGF-C, ICAM-1, survivin, etc. The dysregulation of NF-kB has been linked to developing neurological diseases, immune diseases, and cancer.
The upregulation of NF-kB and related pathways promotes the development and progression of cancer from different angles, including enhancing angiogenesis and altering metabolic and immune status within the tumor microenvironment. Additionally, NF-kB can be activated by chemotherapy and radiotherapy, contributing to treatment failure and resistance. Therefore, different synthetic and natural compounds targeting NF-kB have been discovered and shown to be effective in cancer treatment.
Here, in this Special Issue entitled "Recent Advances in Nuclear Factor kappa-B inhibitors for Cancer Therapy", we aim to cover reviews and original research articles describing the development and use of NF-kB inhibitors in cancer treatments alone or in combination with other cancer treatment modalities (e.g., chemotherapy, radiotherapy, and immunotherapy) from different perspectives. We also encourage the discussion of the NF-kB-mediated regulation of signaling pathways involving cancer progression in an original review. This could be a starting point for developing new NF-kB inhibitors and related strategies for cancer treatment.
Dr. Hui-Yen Chuang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- NF-kB inhibitors
- natural compounds
- metabolism reprogramming
- combination treatments
- treatment resistance